News

This July 15, 2025 SOCS News Update highlights Regine Mathieu, MD's experiences and views on collaboration opportunities.

At So Cal Psych 2025, Monroe discusses the promise of xanomeline-trospium (Cobenfy) and its novel mechanism.

Moderate vitamin D deficiency was not associated with cognitive outcome risk, but severe deficiency was linked to both cognitive impairment and mortality.

Alopecia significantly impacts life quality, with stigma and negative perceptions contributing to mental health issues such as anxiety and depression.

Isaacs and Bellini cover 3 of the most pivotal trial results from the 85th annual American Diabetes Association conference in part 1 of this 2-part recap.

Female sex and recent pregnancy were independent risk factors for reduced likelihood of DAA prescription among people with HCV entering opioid use disorder treatment.

This analysis suggests serum IL-13 levels are lower in bullous pemphigoid patients than in healthy controls and pemphigus vulgaris patients.

Sarcopenia was most prevalent among those on hemodialysis, but prevalence varied based on assessment criteria and timing of lean muscle mass measurement.

Daily intake of baked milk significantly improved tolerance and immune markers in young children with baked milk tolerance, according to a 12-month study.

This review provides guidance to clinicians in choosing effective and safe alopecia therapies during breastfeeding periods.

Already approved by the FDA based on data from the first half of the PaTHway trial, 3-year extended results have indicated lasting efficacy.

Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.

Discover the latest insights on tardive dyskinesia treatment, diagnosis, and the role of VMAT2 inhibitors in enhancing patient well-being.

Auchus discusses his recent presentation on the CATALYST trial, investigating the characteristics of patients with difficult-to-treat T2D because of hypercortisolism.

The previously approved technology has already accomplished over 10,000 procedures for patients with various heart diseases, primarily including atrial fibrillation.

Lifestyle intervention yielded greater maintained weight loss 12 months after discontinuing semaglutide than without.

BaxHTN trial results showed baxdrostat led to a significant reduction of systolic blood pressure compared to placebo, with a favorable safety profile.

Treatment with baxdrostat resolved or reduced the severity of hypertension, excessive aldosterone production, and hypokalemia in the phase 2a SPARK trial.

This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.

Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.

An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

Stay updated with the latest healthcare breakthroughs, including FDA news, clinical trial data, and regulatory submissions, in this week's essential news roundup.

In this video, the last in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fifth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fourth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the third in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the second in a 6-part series, panelists discuss recent advancements in PsO management.